Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Labo Euromedis's Net-Net Working Capital for the quarter that ended in Dec. 2025 was €2.10.
The industry rank for Labo Euromedis's Net-Net Working Capital or its related term are showing as below:
FRA:61R's Price-to-Net-Net-Working-Capital is ranked better than 75% of 24
companies
in the Medical Distribution industry
Industry Median: 6.795
vs FRA:61R: 2.36
Labo Euromedis (FRA:61R) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Labo Euromedis Net-Net Working Capital Related Terms
Labo Euromedis Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:61R vs MCK, COR, CAH: Net-Net Working Capital Comparison
For the Medical Distribution subindustry, Labo Euromedis's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis Price-to-Net-Net-Working-Capital vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of €2.10 mean?
Labo Euromedis (FRA:61R) has a Net-Net Working Capital of €2.10 as of Dec. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Labo Euromedis According to the industry distribution chart, Labo Euromedis ranks #6 out of 24 companies in the Medical Distribution industry, placing it in the top 25%.
Is Labo Euromedis' Net-Net Working Capital too high?
Labo Euromedis' current Net-Net Working Capital is €2.10. Based on the distribution chart, Labo Euromedis ranks #6 out of 24 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Labo Euromedis has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Net-Net Working Capital compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #6 out of 24 companies for Net-Net Working Capital. This places Labo Euromedis in the top 25% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 6.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Distribution company?
The median Net-Net Working Capital among Medical Distribution companies is 6.80, based on 24 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Labo Euromedis For the Medical Distribution industry, the median Net-Net Working Capital is 6.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current Net-Net Working Capital is €2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current Net-Net Working Capital of €2.10. The stock's GF Value™ is €4.38, compared to a current price of €4.86 — trading 11% above its estimated fair value. The current Net-Net Working Capital is €2.10. Labo Euromedis' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current Net-Net Working Capital is €2.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (FRA:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.86 is trading 11% above its estimated GF Value™ of €4.38.
Key valuation signals for FRA:61R:
Net-Net Working Capital: €2.10
GF Value™: €4.38 vs. price of €4.86 (11% above fair value)
No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
62GF Score
Get the complete analysis for FRA:61R
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61R has been successfully added to your 
